Replies to post #189390 on Biotech Values

[jbog]

It's an non-event in my book, there's no new equity being dispensed and it'll only involve a change of ownership.

They have the big boys selling the stock, which I might add has had a nice 25% return since the Abbott transaction less than 6 months ago.

Good Management.

[jbog]

Mylan N.V. (NASDAQ: MYL) today announced the pricing of the underwritten public offering (the "Offering") of 35,000,000 ordinary shares held by certain subsidiaries of Abbott Laboratories ("Abbott"), at $58.35 per share. Abbott has also granted the underwriters an option to purchase an additional 5,250,000 ordinary shares. The net proceeds from the Offering will be approximately $1.99 billion (or $2.29 billion if the option is exercised) after estimated underwriting discounts, commissions and offering expenses. Mylan will not sell any ordinary shares in the Offering and will not receive any of the proceeds from the Offering. The 35,000,000 ordinary shares being sold (or 40,250,000 ordinary shares if the underwriters' option is exercised) represent 31.8% or (36.6% if the option is exercised) of the 110,000,000 ordinary shares currently owned by Abbott.